Immunovant - 53 Year Dividend History | IMVT
Historical dividend payout and yield for Immunovant (IMVT) since 1971. The current TTM dividend payout for Immunovant (IMVT) as of December 20, 2024 is $0.00. The current dividend yield for Immunovant as of December 20, 2024 is 0.00%.
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$3.858B |
$0.000B |
|
Immunovant, Inc. is a clinical-stage biopharmaceutical company, which develops monoclonal antibodies for the treatment of autoimmune diseases. It is developing batoclimab, a novel, fully-human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company is developing batoclimabas a fixed-dose subcutaneous injection for the treatment of autoimmune diseases. It's developing batoclimab with an initial focus on the treatment of myasthenia gravis, an autoimmune disease; thyroid eye disease; and warm autoimmune hemolyticanemia. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd. (RSL). Roivant Sciences GmbH (RSG), a wholly-owned subsidiary of RSL, entered into the HanAll agreement. Per the agreement, RSG received the non-exclusive right to manufacture and exclusively develop, import and use batoclimaband commercialize it in the United States, the EU during the term of the agreement.
|
| Stock Name |
Country |
Market Cap |
PE Ratio |
